KRAS G12C Inhibitors: Acquired Resistance and Combo Strategies

preview_player
Показать описание
Acquired resistance mechanisms to KRAS G12C inhibitors and possible combination strategies being investigated in advanced non–small cell lung cancer.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
Mechanisms of acquired 0:04:29

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

KRAS G12C Inhibitors: 0:05:23

KRAS G12C Inhibitors: Acquired Resistance and Combo Strategies

Mechanisms of resistance 0:03:17

Mechanisms of resistance to KRAS G12C inhibitors

KRAS G12C Inhibitors 0:03:56

KRAS G12C Inhibitors Versus Chemotherapy in Second Line - Targeted Therapies in Lung Cancer 2023

Ascertaining the mechanisms 0:00:44

Ascertaining the mechanisms of resistance to KRASG12C inhibitors

Key lung cancer 0:02:38

Key lung cancer updates: KRAS(G12C) inhibitors and ADCs

Mitigating resistance in 0:05:16

Mitigating resistance in KRAS-driven cancers

Molecular determinants of 0:01:59

Molecular determinants of KRAS G12C inhibitor efficacy in advanced NSCLC

KRAS G12C inhibitors 0:00:58

KRAS G12C inhibitors for GI cancer

KRAS G12C Inhibition 0:02:53

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

Treating KRAS G12C 0:01:42

Treating KRAS G12C Mutations

Optimizing and overcoming 0:01:31

Optimizing and overcoming resistance to current KRAS inhibitors

Aurora A kinase 0:02:00

Aurora A kinase inhibition with VIC-1911 potentiates KRASG12Ci and overcomes resistance

Overcoming acquired resistance 0:01:30

Overcoming acquired resistance to targeted therapy in colorectal cancer

Adagrasib shows CNS 0:04:35

Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC

Barriers to Drug 0:02:56

Barriers to Drug Development for KRAS G12C+ NSCLC - Targeted Therapies in Lung Cancer 2023

KRAS G12C Inhibition 0:04:09

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

Drugging the undruggable: 0:02:29

Drugging the undruggable: a marketreadiness analysis for KRAS-G12C

The potential of 0:10:34

The potential of KRAS inhibitors for non-small-cell lung cancer

Lung Cancer Mutations 0:36:01

Lung Cancer Mutations and Treatment Advances

Safety of sotorasib 0:07:19

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer

Advances in managing 0:01:05

Advances in managing KRASG12C- and EGFR-mutated NSCLC

Unmet needs in 0:00:41

Unmet needs in KRAS-driven non-small cell lung cancer

KRYSTAL-1 and CodeBreak 0:01:26

KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer